Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia

Next Previous
Search
Trial Profile

Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Dementia; Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms MEMORY
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 13 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
    • 18 Oct 2022 According to Lundbeck A/S media release, positive data showing Trintellix/Brintellix (vortioxetine) significantly reduced depressive symptoms and improved cognitive performance in people living with Major Depressive Disorder (MDD) and co-morbid dementia. This data was presented at the 35th European College of Neuropsychopharmacology (ECNP) Congress, October 15-18, 2022, in Vienna, Austria.
    • 18 Oct 2022 Results published in the Lundbeck A/S Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top